This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ZIN-CTI-001

ZIOPHARM Oncology, Inc.

Drug Names(s): DC-IL12, DC-RTS-IL-12, INcell-1001/AD-1001, Adenoviral Transduced Autologous Dendritic Cells, INXN-1001/INXN-3001

Description: INXN-3001 (INCell-1001) are adenoviral transduced autologous dendritic cells engineered to express human interleukin 12 (hIL-12). INXN-3001 cells are injected into a tumor, where the cells are activated by INXN-1001 (AD-1001), an oral small molecule that induces expression of interleukin-12.

The combination immunotherapy utilizes Intrexon's RheoSwitch Therapeutic System to control the in situ timing and level of cytokine expression subsequent to the intratumoral injection reprogrammed autologous dendritic cells. Preclinical studies support the prospective importance of the in situ induction when compared to historical methods utilizing constitutive expression of known anti-tumor cytokines.

Deal Structure: Ziopharm and Intrexon
In January 2011, Ziopharm and Intrexon announced a global exclusive channel partnership in oncology where Ziopharm will develop and commercialize DNA based therapeutics using Intrexon's UltraVector Technology. Under the partnership, Ziopharm will utilize Intrexon's transgene engineering platform for the controlled and precise cellular production of anti-cancer effectors. Ziopharm will have rights to Intrexon's entire human in vivo effector platform within the field of oncology which includes INXN-2001/1001.

The exclusive channel partnership between Intrexon and Ziopharm has been established specifically for the field of human oncologic therapeutics. Under the partnership, Intrexon remains responsible for technology discovery efforts and managing the patent estate as well as for certain aspects of manufacturing. Ziopharm will be responsible for conducting preclinical and clinical development of candidates, as well as for other aspects of...See full deal structure in Biomedtracker

Partners: Intrexon Corporation


ZIN-CTI-001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug